Therefore, in this study, we aimed to combine a checkpoint inhibitor against the CD47–SIRPα axis that has not been previously utilized in combination with CAR-NK therapy to enhance the anti-tumor efficacy of CDH17-targeted CAR-NK cells. Here, CD47 is linked to neoplasm.